Table 1.
Drug targets and representative drugs prioritized in this study
| Disease | Overlap enrichment in disease-relevant ATC codes | Endophenotype MR | Negative correlation tests |
|---|---|---|---|
| Asthma | ibudilast (IL6); omalizumab (FCER1A/FCER1G); alicaforsen (ICAM1) | SAR164653 (CTSA); KHK-2866 (HBEGF); amediplase (PLAU) | donepezil (ACHE); vorinostat (HDAC family); BRD-K50748030 (unknown) |
| POAG | – | – | LY-288513 (unknown) |
| Gout | probenecid (SLC22A6/SLC22A11); lesinurad (SLC22A11/SLC22A12) | anfibatide (GP1BA); berotralstat (KLKB1) | mesoridazine (DRD2/HTR2A); CP-724714 (unknown)a |
| COPD | – | GMA-161 (FCGR3B) | BRD-K48950795 (unknown); RAN-29 (unknown) |
| VTE | alteplase (FGA); edoxaban (F10); ancrod (PROC); dabigatran etexilate (F2); abelacimab (F11); ecallantide (KLKB1); drotrecogin alfa (F5) | abelacimab (F11); CR-002 (PDGFB) | WH-4025 (unknown) |
| ThC | – | tosedostat (XPNPEP2) | (excluded from the analysis) |
| AAA | – | MG-1102 (LPA); amediplase (PLAU) | (excluded from the analysis) |
| HF | – | MG-1102 (LPA) | – |
| IPF | – | – | – |
| Stroke | – | – | – |
| UtC | – | Anfibatide (GP1BA) | – |
| AcApp | – | GNF-PF-5434 (CTSB) | (excluded from the analysis) |
| HCM | – | – | – |
The diseases are sorted in the decreasing order of the number of the genome-wide significant loci in GBMI GWAS.
a
Drugs without known target genes were not shown except for the drug with the lowest p value, CP-724714. Full results can be found in Table S2.